Surface Oncology Reports Financial Results and Corporate Highlights for Third Quarter 2019
12 nov. 2019 06h30 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Presents Updates at the Society for Immunotherapy of Cancer’s Annual Meeting
07 nov. 2019 08h00 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology to Host Analyst and Investor Day on November 18, 2019 in New York City
07 oct. 2019 07h00 HE
|
Surface Oncology, Inc.
Keynote speaker: E. John Wherry, Ph.D., director, Penn Institute for Immunology, University of Pennsylvania, and Co-Director of the Parker Institute for Cancer Immunotherapy at PennPresentations from...
Surface Oncology to Present at the Baird 2019 Global Healthcare Conference
03 sept. 2019 16h05 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Ramy Ibrahim, M.D. to Join Surface Oncology Board of Directors
03 sept. 2019 07h00 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), today announced Ramy Ibrahim, M.D., will join the company’s board of directors. Dr. Ibrahim is a medical...
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2019
07 août 2019 06h05 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology to Participate in 40th Annual Goldman Sachs Global Healthcare Conference
07 juin 2019 12h00 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., June 07, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Presents Preclinical Data Further Supporting Anti-Tumor Mechanism of CD73 and CD39 Programs at Brisbane Immunotherapy 2019
24 mai 2019 06h00 HE
|
Surface Oncology, Inc.
Presentation provides updated in vivo efficacy data supporting adenosine reduction for cancer treatmentData also support anti-CD39 candidate’s capability to invoke both innate and adaptive immune...
Surface Oncology to Present at Two Upcoming Healthcare Conferences
15 mai 2019 16h00 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., May 15, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2019
09 mai 2019 07h00 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...